COMMUNIQUÉS West-GlobeNewswire

Hoth Therapeutics Inc. Announces the Addition of Dr. Adam Friedman, M.D. to the Company's Scientific Advisory Board
25/02/2019
NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Hoth Therapeutics, Inc.(NASDAQ:HOTH), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as [...]
Humanigen Study of GM-CSF Neutralization With CAR-T Therapy Accepted as Oral Presentation at the 2019 Transplantation & Cellular Therapy (TCT) Annual Meeting
25/02/2019
First ever demonstration that the spectrum of toxicities seen in CAR-T clinical trials can be effectively prevented in vivo Enhanced anti-tumor activity, improved overall survival, and improved durability of response [...]
TYME Receives FDA Guidance on Pivotal Trial for SM-88 in Treatment for Advanced Pancreatic Cancer
25/02/2019
NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing metabolic-based cancer therapies, announced that it received design guidance for a [...]
Galectin Therapeutics to Present at Berenberg NASH Day in New York
25/02/2019
NORCROSS, Ga., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H. Shlevin, the Company’s [...]
VBI Vaccines Provides Corporate Update, Outlook for 2019, and Year-End 2018 Financial Results
25/02/2019
Top-line data from Hepatitis B (Sci-B-Vac®) Phase 3 PROTECT trial expected mid-year 2019 Encouraging early immunogenicity data from GBM Phase 1/2a supports advancing into Part B of the study License and Collaboration [...]
Progressive Care Inc. Garners Coverage in CBS Miami for Creating Custom-Made Lotion Alternatives to Opioids
25/02/2019
MIAMI, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Progressive Care Inc. ( OTCQB: RXMD ), a personalized healthcare services and technology company, today announced that it has garnered media coverage in CBS Miami for creating [...]
Eidos Therapeutics to Host Conference Call and Webcast to Discuss ATTR-CM Phase 3 Trial (ATTRibute-CM) Design
25/02/2019
SAN FRANCISCO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need caused by transthyretin [...]
CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001
25/02/2019
-First patient infused with CTX001 in a Phase 1/2 clinical trial for patients with beta thalassemia- - First patient enrolled in a Phase 1/2 clinical trial of CTX001 for patients with sickle cell disease- ZUG, [...]
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2018 Financial Results on March 18, 2019
25/02/2019
CANTON, Mass., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions [...]
NanoVibronix Announces Publication of PainShield™ Trigeminal Neuralgia Study in the Journal of Anesthesiology and Pain Research
25/02/2019
55.2% improvement in baseline pain scores versus 2.3% for the control group 46.4% reduction in breakthrough pain medication, including opioids, versus 1.5% versus for the treatment group PainShield™ had no adverse [...]
CEO of TRHC’s New Research & Development Institute to Present at National University of Singapore
25/02/2019
MOORESTOWN, N.J., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc . (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, today announced that TRHC’s Chief [...]
Inovalon to Present at Morgan Stanley Technology, Media & Telecom Conference
25/02/2019
BOWIE, Md., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq: INOV), a leading technology company providing advanced, cloud-based platforms empowering data-driven healthcare, today announced that Keith Dunleavy, M.D [...]
Ziopharm Oncology to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on March 5
25/02/2019
BOSTON, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast slide presentation on Tuesday, March 5, at 4:30 p.m. ET to provide [...]
Blueberries Medical Enters into Agreement with a Leading Colombian Craft Brewer to Pioneer the Development and Commercialization of Cannabis Based Beverages in Latin America
25/02/2019
TORONTO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (the “ Company ” or " Blueberries ") a leading Colombia-based licensed producer of medicinal cannabis and cannabis-derived products, [...]
ADMA Biologics to Present at Upcoming Investor Conferences
25/02/2019
Raymond James 40 th Annual Institutional Investors Conference Oppenheimer’s 29 th Annual Healthcare Conference RAMSEY, N.J. and BOCA RATON, Fla., Feb. 25, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ [...]
REVA Announces Extension to Voluntary Suspension of Trading
25/02/2019
SAN DIEGO, Feb. 24, 2019 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) said today that on 25 February 2019 (AEDT), the Australian Securities Exchange issued a market announcement indicating [...]
Philips showcases unique augmented reality concept for image-guided minimally invasive therapies developed with Microsoft
24/02/2019
February 24, 2019 Companies collaborate to combine Philips’ industry-leading Azurion image-guided therapy platform with Microsoft HoloLens 2 mixed reality computing platform as a concept for the operating room of the [...]
BioCryst Reports ZENITH-1 Results With Oral BCX7353 Which Confirm Rapid Onset of Action, Sustained Activity and Robust Dose Response for Treatment of Acute HAE Attacks
23/02/2019
— Based on ZENITH-1 data, company plans to commence Phase 3 trial of single-dose 750 mg oral BCX7353 for acute treatment of hereditary angioedema (HAE) attacks in summer 2019— —Data show excellent clinical dose response [...]
FibroGen Reports Fourth Quarter and Full Year 2018 Financial Results
23/02/2019
SAN FRANCISCO, Feb. 22, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today announced that it will [...]

Pages